BRD2 and ductal breast carcinoma in situ: We observed that SEMA7A increased in 85.7% of DCIS compared to NAT in TMA1 (Fig. 1A, Supp Fig. 1C); in TMA2, we observed increased SEMA7A in 86.1% of DCIS compared to NAT and increased SEMA7A in 66.7% of IDC compared to DCIS (Fig. 1D, Supp Fig. 1C).